Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas

Scott M. Irwin, Veronica Gruppo, Elizabeth Brooks, Janet Gilliland, Michael Scherman, Matthew J. Reichlen, Rachel Leistikow, Igor Kramnik, Eric Nuermberger, Martin I. Voskuil, Anne J. Lenaerts

Research output: Contribution to journalArticle

Abstract

New drugs and drugs with a novel mechanism of action are desperately needed to shorten the duration of tuberculosis treatment, to prevent the emergence of drug resistance, and to treat multiple-drug-resistant strains of Mycobacterium tuberculosis. Recently, there has been renewed interest in clofazimine (CFZ). In this study, we utilized the C3HeB/FeJ mouse model, possessing highly organized, hypoxic pulmonary granulomas with caseous necrosis, to evaluate CFZ monotherapy in comparison to results with BALB/c mice, which form only multifocal, coalescing cellular aggregates devoid of caseous necrosis. While CFZ treatment was highly effective in BALB/c mice, its activity was attenuated in the lungs of C3HeB/FeJ mice. This lack of efficacy was directly related to the pathological progression of disease in these mice, since administration of CFZ prior to the formation of hypoxic, necrotic granulomas reconstituted bactericidal activity in this mouse strain. These results support the continued use of mouse models of tuberculosis infection which exhibit a granulomatous response in the lungs that more closely resembles the pathology found in human disease.

Original languageEnglish (US)
Pages (from-to)4026-4034
Number of pages9
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Clofazimine
Granuloma
Tuberculosis
Pharmaceutical Preparations
Lung
Necrosis
Mycobacterium tuberculosis
Drug Resistance
Disease Progression
Pathology

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Irwin, S. M., Gruppo, V., Brooks, E., Gilliland, J., Scherman, M., Reichlen, M. J., ... Lenaerts, A. J. (2014). Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrobial Agents and Chemotherapy, 58(7), 4026-4034. https://doi.org/10.1128/AAC.02565-14

Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. / Irwin, Scott M.; Gruppo, Veronica; Brooks, Elizabeth; Gilliland, Janet; Scherman, Michael; Reichlen, Matthew J.; Leistikow, Rachel; Kramnik, Igor; Nuermberger, Eric; Voskuil, Martin I.; Lenaerts, Anne J.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 7, 2014, p. 4026-4034.

Research output: Contribution to journalArticle

Irwin, SM, Gruppo, V, Brooks, E, Gilliland, J, Scherman, M, Reichlen, MJ, Leistikow, R, Kramnik, I, Nuermberger, E, Voskuil, MI & Lenaerts, AJ 2014, 'Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas', Antimicrobial Agents and Chemotherapy, vol. 58, no. 7, pp. 4026-4034. https://doi.org/10.1128/AAC.02565-14
Irwin, Scott M. ; Gruppo, Veronica ; Brooks, Elizabeth ; Gilliland, Janet ; Scherman, Michael ; Reichlen, Matthew J. ; Leistikow, Rachel ; Kramnik, Igor ; Nuermberger, Eric ; Voskuil, Martin I. ; Lenaerts, Anne J. / Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 7. pp. 4026-4034.
@article{41a97f883fec4cf1b6bd0f108abc316a,
title = "Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas",
abstract = "New drugs and drugs with a novel mechanism of action are desperately needed to shorten the duration of tuberculosis treatment, to prevent the emergence of drug resistance, and to treat multiple-drug-resistant strains of Mycobacterium tuberculosis. Recently, there has been renewed interest in clofazimine (CFZ). In this study, we utilized the C3HeB/FeJ mouse model, possessing highly organized, hypoxic pulmonary granulomas with caseous necrosis, to evaluate CFZ monotherapy in comparison to results with BALB/c mice, which form only multifocal, coalescing cellular aggregates devoid of caseous necrosis. While CFZ treatment was highly effective in BALB/c mice, its activity was attenuated in the lungs of C3HeB/FeJ mice. This lack of efficacy was directly related to the pathological progression of disease in these mice, since administration of CFZ prior to the formation of hypoxic, necrotic granulomas reconstituted bactericidal activity in this mouse strain. These results support the continued use of mouse models of tuberculosis infection which exhibit a granulomatous response in the lungs that more closely resembles the pathology found in human disease.",
author = "Irwin, {Scott M.} and Veronica Gruppo and Elizabeth Brooks and Janet Gilliland and Michael Scherman and Reichlen, {Matthew J.} and Rachel Leistikow and Igor Kramnik and Eric Nuermberger and Voskuil, {Martin I.} and Lenaerts, {Anne J.}",
year = "2014",
doi = "10.1128/AAC.02565-14",
language = "English (US)",
volume = "58",
pages = "4026--4034",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas

AU - Irwin, Scott M.

AU - Gruppo, Veronica

AU - Brooks, Elizabeth

AU - Gilliland, Janet

AU - Scherman, Michael

AU - Reichlen, Matthew J.

AU - Leistikow, Rachel

AU - Kramnik, Igor

AU - Nuermberger, Eric

AU - Voskuil, Martin I.

AU - Lenaerts, Anne J.

PY - 2014

Y1 - 2014

N2 - New drugs and drugs with a novel mechanism of action are desperately needed to shorten the duration of tuberculosis treatment, to prevent the emergence of drug resistance, and to treat multiple-drug-resistant strains of Mycobacterium tuberculosis. Recently, there has been renewed interest in clofazimine (CFZ). In this study, we utilized the C3HeB/FeJ mouse model, possessing highly organized, hypoxic pulmonary granulomas with caseous necrosis, to evaluate CFZ monotherapy in comparison to results with BALB/c mice, which form only multifocal, coalescing cellular aggregates devoid of caseous necrosis. While CFZ treatment was highly effective in BALB/c mice, its activity was attenuated in the lungs of C3HeB/FeJ mice. This lack of efficacy was directly related to the pathological progression of disease in these mice, since administration of CFZ prior to the formation of hypoxic, necrotic granulomas reconstituted bactericidal activity in this mouse strain. These results support the continued use of mouse models of tuberculosis infection which exhibit a granulomatous response in the lungs that more closely resembles the pathology found in human disease.

AB - New drugs and drugs with a novel mechanism of action are desperately needed to shorten the duration of tuberculosis treatment, to prevent the emergence of drug resistance, and to treat multiple-drug-resistant strains of Mycobacterium tuberculosis. Recently, there has been renewed interest in clofazimine (CFZ). In this study, we utilized the C3HeB/FeJ mouse model, possessing highly organized, hypoxic pulmonary granulomas with caseous necrosis, to evaluate CFZ monotherapy in comparison to results with BALB/c mice, which form only multifocal, coalescing cellular aggregates devoid of caseous necrosis. While CFZ treatment was highly effective in BALB/c mice, its activity was attenuated in the lungs of C3HeB/FeJ mice. This lack of efficacy was directly related to the pathological progression of disease in these mice, since administration of CFZ prior to the formation of hypoxic, necrotic granulomas reconstituted bactericidal activity in this mouse strain. These results support the continued use of mouse models of tuberculosis infection which exhibit a granulomatous response in the lungs that more closely resembles the pathology found in human disease.

UR - http://www.scopus.com/inward/record.url?scp=84903188913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903188913&partnerID=8YFLogxK

U2 - 10.1128/AAC.02565-14

DO - 10.1128/AAC.02565-14

M3 - Article

C2 - 24798275

AN - SCOPUS:84903188913

VL - 58

SP - 4026

EP - 4034

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -